Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Capital Expenditures (2016 - 2025)

Enanta Pharmaceuticals' Capital Expenditures history spans 14 years, with the latest figure at $143000.0 for Q4 2025.

  • For Q4 2025, Capital Expenditures fell 98.36% year-over-year to $143000.0; the TTM value through Dec 2025 reached $4.3 million, down 83.62%, while the annual FY2025 figure was $12.9 million, 28.15% down from the prior year.
  • Capital Expenditures reached $143000.0 in Q4 2025 per ENTA's latest filing, down from $11.5 million in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $11.5 million in Q3 2025 to a low of -$9.9 million in Q2 2025.
  • Average Capital Expenditures over 5 years is $1.7 million, with a median of $421000.0 recorded in 2021.
  • The largest YoY upside for Capital Expenditures was 2459.79% in 2023 against a maximum downside of 1975.63% in 2023.
  • A 5-year view of Capital Expenditures shows it stood at $363000.0 in 2021, then soared by 197.25% to $1.1 million in 2022, then crashed by 55.61% to $479000.0 in 2023, then surged by 1725.68% to $8.7 million in 2024, then plummeted by 98.36% to $143000.0 in 2025.
  • Per Business Quant, the three most recent readings for ENTA's Capital Expenditures are $143000.0 (Q4 2025), $11.5 million (Q3 2025), and -$9.9 million (Q2 2025).